A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Basit Öğe Kaydı
dc.authorscopusidMeral Beksaç / 56924887200
dc.authorwosidMeral Beksaç / JJK-2013-2023
dc.contributor.authorDimopoulos, Meletios A.
dc.contributor.authorCoriu, Daniel
dc.contributor.authorDelimpasi, Sosana
dc.contributor.authorŠpička, Ivan
dc.contributor.authorUpchurch, Terry
dc.contributor.authorFang, Belle
dc.contributor.authorTalpur, Rakhshandra
dc.contributor.authorFaber, Edward
dc.contributor.authorBeksaç, Meral
dc.contributor.authorLeleu, Xavier
dc.date.accessioned2025-06-03T13:34:00Z
dc.date.available2025-06-03T13:34:00Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractTwice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27) is a standard of care in relapsed/refractory multiple myeloma (RRMM). Once-weekly carfilzomib regimens have shown clinical benefits with improved patient convenience. This open-label, phase 3, multicenter, randomized study aimed to demonstrate noninferiority of the overall response rate (ORR) for once-weekly carfilzomib (56 mg/m2) plus Rd (KRd56) vs twice-weekly KRd27 in RRMM. A total of 454 patients were randomized (1:1) to receive carfilzomib as onceweekly 30-minute infusions of 56 mg/m2 (KRd56; n = 228) or twice-weekly 10-minute infusions of 27 mg/m2 (KRd27; n = 226). Baseline characteristics were balanced between groups. ORR was 82.5% (95% confidence interval [CI], 76.9-87.2) in the once-weekly group vs 86.3% (95% CI, 81.1-90.5) in the twice-weekly group (risk ratio, 0.954 [95% CI, 0.882-1.032]) and did not meet the threshold for statistical significance of noninferiority (P = .0666). Complete response (CR) or better was obtained in 46.9% of patients in the once-weekly arm and 36.3% in the twice-weekly arm. The proportions of patients who achieved CR and were also assessed negative forminimal residual disease were 21.5% and 18.1%, respectively (odds ratio, 1.235 [95% CI, 0.775-1.970]). Progression-free survival was comparable between groups (hazard ratio, 0.945 [95% CI, 0.617-1.447]). The safety profile was similar for both groups. In conclusion, although statistical significance for noninferiority of ORR was not achieved, the efficacy and safety of once-weekly KRd56 were similar to those of twice-weekly KRd27, and once-weekly KRd56 may be an effective and convenient treatment option for patients with RRMM. © 2024 by The American Society of Hematology.
dc.description.sponsorshipThis work was supported by research funding from Amgen Inc. Swapnil Kher and Manoj Kumar Goyal of Cactus Life Sciences (part of Cactus Communications) provided medical writing and editorial assistance, funded by Amgen Inc. Graphics support was provided by Bob Dawson of Cactus Communications and funded by Amgen Inc.
dc.identifier.citationDimopoulos, M. A., Coriu, D., Delimpasi, S., Špička, I., Upchurch, T., Fang, B., ... & Leleu, X. (2024). ARROW 2: once-vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Blood Advances, 8(19), 5012-5021.
dc.identifier.doi10.1182/bloodadvances.2024013101
dc.identifier.endpage5021
dc.identifier.issn24739529
dc.identifier.issue19
dc.identifier.pmid39024542
dc.identifier.scopusqualityQ1
dc.identifier.startpage5012
dc.identifier.urihttp://dx.doi.org/10.1182/bloodadvances.2024013101
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7285
dc.identifier.volume8
dc.identifier.wosWOS:001327754300001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorBeksaç, Meral
dc.institutionauthoridMeral Beksaç / 0000-0003-1797-8657
dc.language.isoen
dc.publisherAmerican Society of Hematology
dc.relation.ispartofBlood Advances
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDexamethasone
dc.subjectLenalidomide
dc.titleA.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Artificial-intelligence-in-reproductive-endocrinology-an-indepth-longitudinal-analysis-of-ChatGPTv4s-monthbymonth-interpretation-and-adherence-to-clinical-guidelines-for-diminished-ovarian-reserveEndocrine.pdf
Boyut:
993.07 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Temel Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu